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Background. Nontyphoidal Salmonella (NTS) organisms are a major cause of gastroenteritis and bacteremia, but little is known 
about maternally acquired immunity and natural exposure in infant populations residing in areas where NTS disease is highly 
endemic.
Methods. We recruited 503 pregnant mothers and their infants (following delivery) from urban areas in Vietnam and fol-
lowed infants until they were 1 year old. Exposure to the dominant NTS serovars, Salmonella enterica serovars Typhimurium and 
Enteritidis, were assessed using lipopolysaccharide (LPS) O antigen–specific antibodies. Antibody dynamics, the role of maternally 
acquired antibodies, and NTS seroincidence rates were modeled using multivariate linear risk factor models and generalized additive 
mixed-effect models.
Results. Transplacental transfer of NTS LPS–specific maternal antibodies to infants was highly efficient. Waning of transpla-
centally acquired NTS LPS–specific antibodies at 4 months of age left infants susceptible to Salmonella organisms, after which they 
began to seroconvert. High seroincidences of S. Typhimurium and S. Enteritidis LPS were observed, and infants born with higher 
anti-LPS titers had greater plasma bactericidal activity and longer protection from seroconversion.
Conclusions. Although Vietnamese infants have extensive exposure to NTS, maternally acquired antibodies appear to play a 
protective role against NTS infections during early infancy. These findings suggest that prenatal immunization may be an appropriate 
strategy to protect vulnerable infants from NTS disease.
Keywords. Nontyphoidal Salmonella; NTS; Vietnam; Salmonella Typhimurium; Salmonella Enteritidis; maternal antibodies; 
infant antibodies; seroincidence; seroepidemiology; transplacentally acquired immunity; maternal immunization.
 
Nontyphoidal Salmonella (NTS) organisms are a signifi-
cant cause of diarrhea and bloodstream infections globally 
[1]. In 2010, gastroenteritis-associated NTS bacteria caused 
an estimated 93.8 million cases and 155 000 deaths globally, 
with the highest burden in children of developing countries 
[2]. More-severe, extraintestinal NTS infections, known as 
invasive NTS disease, occurred in approximately 3.4 mil-
lion individuals globally. The estimated case-fatality rate of 
invasive NTS disease was 20% in 2010, with 63.7% of fatal 
cases occurring in children aged <5  years of age [3]. Rising 
levels of antimicrobial resistance are likely to compound inva-
sive NTS disease morbidity and mortality. Salmonella enterica 
serovars Typhimurium and Enteritidis are the first- and sec-
ond-most commonly isolated Salmonella from humans world-
wide, respectively [4], constituting >60% of all Salmonella 
bacteria isolated from humans [4]. Consequently, bivalent S. 
Typhimurium and S. Enteritidis vaccine formulations are a 
current focus for development of a human NTS vaccine [5]. 
However, a lack of accurate data regarding natural exposure 
and infant immunity to NTS has impaired evidence-based 
recommendations for vaccine development, scheduling, and 
implementation.
Antibodies play a critical role in protective immunity against 
NTS infections. Several outer-membrane Salmonella antigens, 
including lipopolysaccharide (LPS; which encompasses the 
O antigen), are targets of human antibodies following natural 
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infections [6, 7]. NTS-specific immunoglobulin A  (IgA) anti-
bodies in the gut have been shown to reduce bacterial entry 
into epithelial cells [8], whereas NTS-specific immunoglobulin 
G (IgG) antibodies in the blood have been shown to protect 
against invasive NTS disease through cell-mediated mecha-
nisms and complement membrane attack complexes [9, 10]. 
For many infectious pathogens, maternally acquired antibodies 
transferred during pregnancy or through breast milk provide an 
important additional layer of protection during the infant’s first 
months of life [11–15]. In the case of NTS infections, several 
studies using animal models have indicated a potential role for 
placentally transferred maternal NTS-specific IgG and breast 
milk IgA in protecting newborns [16, 17]. Similarly, studies 
from Malawi have suggested that a lack of symptomatic NTS 
infections in the first months of infant life may be associated 
with the transfer and persistence of maternal antibodies [9, 18]. 
However, given the paucity of available longitudinal mater-
nal and infant data, it is unclear whether maternally acquired 
immunity plays a significant protective role against NTS organ-
isms in a low-to-middle-income setting where NTS is highly 
endemic.
The transfer, longevity, and role of anti-NTS maternal anti-
bodies in infants have not been defined. Furthermore, because of 
underreporting and subclinical disease, the true burden of NTS 
infection and exposure in infants is difficult to accurately define. 
NTS infections in children represent a large public health bur-
den in Vietnam, where 4% of pediatric hospitalized diarrheal 
disease cases and 18% of infant diarrheal disease cases in the 
community have been reported to be associated with NTS [19, 
20]. We aimed to assess the dynamics of anti-Salmonella anti-
body in the first year of life in an urban cohort of infants in Ho 
Chi Minh City (HCMC), Vietnam. We measured the transfer 
and decay of anti-NTS maternal antibodies in infants, estimated 
the true incidence of NTS exposure (through the progression of 
the S. Typhimurium and S. Enteritidis O antigen IgG response), 
and finally assessed the potential of transplacentally acquired 
antibodies in protecting infants against NTS infections.
METHODS
Study Design and Ethics
The current study was a component of a larger prospective birth 
cohort study conducted in Vietnam, for which a detailed descrip-
tion has been published previously [19, 21]. Mothers and infants 
were participants from the mentioned birth cohort study who 
were recruited between January and December 2013 at Hung 
Vuong Obstetrics Hospital in HCMC. Briefly, healthy pregnant 
woman aged >15 years who were HIV seronegative and living 
in an urban district (District 8) of HCMC were invited to par-
ticipate in the study. Umbilical cord and venous maternal blood 
samples were collected immediately following delivery. Infants 
were enrolled into the study after birth, and baseline information 
related to the mother and the infant’s health after delivery was 
recorded within 72 hours after birth. After delivery, infants were 
called back regularly for routine follow-up visits until 1  year 
of age, with blood samples collected at 4- or 6-month visits, 
9-month, and 12-month visits. All blood samples were separated 
into cells and plasma and stored at −20°C until further use. This 
study was approved by the Institutional Review Board of Hung 
Vuong Obstetric Hospital and the Oxford Tropical Research 
Ethics Committee (OxTREC). All participating mothers pro-
vided written informed consent for themselves and their infants.
Plasma and stool samples for validation of O antigen–specific 
enzyme-linked immunosorbent assay (ELISA) findings were 
obtained from a previously published study [22]. Multiplex 
polymerase chain reaction (PCR) analyses were conducted on 
stool samples culture positive for Salmonella, for identification 
of the infecting Salmonella serovars. Further details are availa-
ble in the Supplementary Materials and Supplementary Table 1.
S. Typhimurium and S. Enteritidis O Antigen ELISAs
ELISAs were used to quantify plasma antibodies targeting 
O antigen of S. Typhimurium (O4) and S. Enteritidis (O9), 
as previously described for S. Typhi [23, 24]. Briefly, ELISA 
plates were coated with Toll-like receptor–grade smooth form 
of LPS (Enzo Life Sciences, UK) from S. Typhimurium or S. 
Enteritidis at 0.5 mg/mL and incubated overnight at 4°C. Plates 
were blocked with 5% nonfat dried milk in phosphate-buffered 
saline for 2 hours at room temperature, and incubated with 
plasma samples (1:200 diluted in 1% nonfat dried milk buffer) 
for 2 hours at room temperature. LPS-binding antibodies were 
detected using alkaline phosphatase-conjugated anti-human 
IgG and immunoglobulin M (IgM) secondary antibodies (for 
1 hour at ambient room temperature), and developed using 
p-nitrophenyl-phosphate solution (SigmaFAST N1891; Sigma-
Aldrich, UK), with absorbance measured at 405 and 490nm. 
The OD of each sample was then converted to ELISA units (EU) 
per milliliter, using a reference standard as previously described 
[24]. The reference standard on each plate contained ten 2-fold 
dilutions, starting from a 1:200 dilution. A standard curve was 
generated from corresponding ODs, using a 4-parameter logis-
tic regression fit, where 1 EU was the reciprocal of the dilution 
of the reference standard that gave an OD of 1. The reference 
standard was a pool of known anti-O antigen–positive human 
sera generated from a bank of Vietnamese plasma.
Serum Bactericidal Assay
A selection of infant plasma samples with high (>1000 EU; 
n = 11) and low (<50 EU; n = 9) binding antibody titers were tested 
for bactericidal killing activity against a Vietnamese clinical iso-
late of S. Typhimurium (VNS20081; isolated from a Vietnamese 
child with diarrhea [22]), using a previously described proce-
dure [25]. Briefly, heat-inactivated plasma samples were serially 
diluted 2-fold from 1:50 to 1:6400 in phosphate-buffered saline 
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containing 1% bovine serum albumin, 33  mg/mL CaCl2, and 
0.041% MgCl2.6H2O. S. Typhimurium was grown to mid-log 
phase (OD  =  0.4) and diluted to approximately 250–300 col-
ony-forming units (CFU)/well. Baby rabbit complement was 
added to a final concentration of 25% and incubated at 37°C for 
another 60 minutes. S. Typhimurium bacteria were enumerated 
at time 0 (T0) and after incubation for 60 minutes (T60) by plat-
ing on nutrient agar plates. Bactericidal activity was expressed 
as a ratio between T60 and T0 (calculated as the number of CFU 
at T60 divided by the number at T0), and the serum bactericidal 
titer at 50% bactericidal effect was calculated. Each plasma sam-
ple was tested in triplicate and averaged.
Statistical Analysis
Comparisons between groups of continuous data were con-
ducted using the nonparametric test, Mann-Whitney U test. 
Comparisons between continuous data of paired samples were 
conducted using the paired Wilcoxon test. After the normal-
ity of the IgG titer distribution was tested using the Shapiro-
Wilk normality test, correlation between newborn and 
maternal IgG titers were tested using the Pearson correlation 
test. Seroincidence rates were calculated as the number of sero-
conversions divided by the number of infant-years, multiplied 
by 1000, where seroconversion was defined as at least a 2-fold 
increase in IgG titer. Seroincidence rates between periods were 
compared using the Wald test.
Risk factors affecting the transfer ratio of anti-O4 and anti-O9 
IgG (calculated as the neonatal IgG titer divided by the maternal 
IgG titer) were assessed using a linear regression model, with the 
log10-transformed IgG transfer ratio as the dependent variable. 
Thirteen variables (Tables 2 and 3) were chosen on the basis of 
past evidence or the potential for affecting maternal-infant IgG 
transfer [26, 27]. Univariable linear regression was followed by 
multivariable regression modeling with these 13 variables and 
backward stepwise elimination using the Akaike information 
criterion (AIC) as best-fit criteria.
Time series data of anti-O4 and anti-O9 IgM and IgG titers 
in infants during the 12-month study follow up period were fit-
ted to generalized additive mixed-effect models (GAMM), with 
adjustments for random intercepts and slopes. Smooth, nonlin-
ear GAMMs were fitted to the data by using the R packages mgcv 
and itsadug. Because the log10 transformation of 0 yields a value 
of infinity, for modeling and graphical purposes data points with 
values of 0 EU were substituted with a small value (ie, 0.00001).
RESULTS
O Antigen Antibodies Identify S. Typhimurium and S. Enteritidis Infections
A rise in titers of IgM and IgG antibodies specific to 
S. Typhimurium O4 and S. Enteritidis O9 antigens is indicative of a 
recent infection with Salmonella bacteria [28, 29]. To confirm that 
such a rise was also evident in Vietnamese children, we conducted 
a series of ELISAs on paired plasma samples (obtained during the 
acute and convalescent phases) collected during a prior study [22] 
from children residing in HCMC and presenting with acute diar-
rhea associated with culture-confirmed S. Typhimurium (n = 36), 
S. Enteritidis (n  =  6), other group B (O4) Salmonella (n  =  20), 
other group D (O9) Salmonella (n  =  2), and Shigella (n  =  31) 
infections. In these patient samples, both anti-O4 IgM and IgG 
exhibited a significantly greater median fold increase after infec-
tion with S. Typhimurium (4.2-fold and 4.9-fold, respectively) 
than infection with non–group B NTS (1.0-fold and 0.9-fold, 
respectively) or Shigella organisms (1.2-fold and 1.04-fold, respec-
tively; Supplementary Figure 1A and 1B). Similarly, we observed 
an increase in anti-O9 IgM and IgG titers between paired sam-
ples following infection with S. Enteritidis (2.4-fold and 3.1-fold, 
respectively) and other group D Salmonella organisms (6.3-fold 
and 9.0-fold, respectively; Supplementary Figure 1C and 1D). Our 
data show that these O antigen ELISAs were sufficiently specific 
to detect and differentiate infection with group B and group D 
Salmonella bacteria from infection with non-NTS organisms.
Maternal Transfer of Salmonella-Specific Antibodies to Newborns
We enrolled 503 pregnant mothers with a median age of 28 years 
(interquartile range, 25–31  years) and enrolled their infants 
following delivery (Table  1). Approximately 9% of enrolled 
Table 1. Baseline Characteristics of 503 Participating Mother-Infant Pairs
Characteristic Value
Mothers
 Age, y 28 (25–31)
 Education level, higher secondary or above 248 (49.3)
 Gravidity 2 (1–3)
 Pregnancy complication 45 (8.95)
 Fever from infection during pregnancy 24 (4.8)
 Diabetes 22 (4.4)
 Hypertension 34 (6.8)
 Anemia 34 (6.8)
 Smoking or passive smoking during pregnancy 194 (38.6)
 IgG level, EU/mL, GMT (95% CI)
  To anti-O4 antigen 191 (178–204)
  To anti-O9 antigen 160 (149–172)
Infants
 Male sex 260 (51.7)
 Gestation age, wk 39 (38–40)
 Preterm birth 21 (4.2)
 Birth weight, kg 3·15 (2.90–3.40)
 Low birth weight 23 (4.6)
 Vaginal delivery 288 (57.3)
 Exclusive breastfeeding
  During first month of life 215 (43)
  During first 4 months of life 93 (18)
 IgG level, EU/mL, GMT (95% CI)
  To anti-O4 antigen 252 (234–271)
  To anti-O9 antigen 177 (163–193)
Data are no. (%) of participants or median value (interquartile range), unless otherwise 
indicated.
Abbreviations: CI, confidence interval; GMT, geometric mean titer; IgG, immunoglobulin G.
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mothers (45 of 503)  had complications during pregnancy, 7% 
(34 of 503) experienced hypertension, and 4.4% (22 of 503) were 
diabetic. Among the enrolled infants, the sex of 52% (260 of 
503) was male, 4.2% (21 of 503) were preterm, and 4.6% (23 of 
503) had a low birth weight. We performed anti-O4 and anti-O9 
IgG ELISAs on plasma and placental cord blood specimens from 
503 participating mothers following delivery. The anti-O4 IgG 
geometric mean titers were 191 EU/mL (95% confidence interval 
[CI], 178–204) in participating mothers and 252 EU/mL (95% CI, 
234–271) in infants at birth (Table 1). Similarly, the maternal and 
infant anti-O9 IgG geometric mean titers were 160 EU/mL (95% 
CI, 149–172) and 177 EU/mL (95% CI, 163–193), respectively.
We next assessed maternal antibody transfer of anti- 
S. Typhimurium (anti-O4) and anti-S. Enteritidis (anti-O9) IgG 
from mothers to newborns. There was significant linear correla-
tion between maternal IgG titers and infant titers for both O4 and 
O9 (correlation coefficients, 0.85 (P < .0001) and 0.87 (P < .0001), 
respectively; Figure 1). Maternal anti-O4 and anti-O9 IgG were 
efficiently transferred to newborns, with mean transfer ratios 
(calculated is the newborn IgG titer divided by the maternal IgG 
titer) of >1 (ie, 1.45 [95% CI, 1.39–1.51] and 1.23 [95% CI, 1.17–
1.30], respectively). Furthermore, a positive correlation (r = 0.69; 
P < .0001) was observed between anti-O4 and anti-O9 IgG titers 
in the maternal samples (Supplementary Figure 2).
Risk factor analysis was conducted to identify maternal and 
infant variables associated with the transfer of anti-O4 and 
anti-O9 IgG antibodies from mothers to infants. A  multivar-
iate linear regression analysis with log10-transformed anti-O4 
IgG transfer ratios identified several variables associated with 
maternal antibody transfer. These factors included a positive 
correlation with maternal hypertension (P = .027) and a weak 
positive correlation with female infants (P  =  .085), whereas 
maternal anti-O4 IgG titer, preterm birth, and irregular vaginal 
bleeding negatively correlated with the transfer ratio (P = .0006, 
0.012, and 0.061, respectively; Table 2). A similar multivariable 
linear regression analysis conducted with log10-transformed 
anti-O9 IgG transfer ratios identified female children and 
maternal hypertension as also being positively associated with 
the anti-O9 IgG transfer ratio (P = .028 and P = .048, respec-
tively); preterm birth and irregular vaginal bleeding showed 
only weak evidence for a negative association (Table 3).
Seroconversion During the First Year of Life
Enrolled newborns were followed-up for 12 months, and anti-S. 
Typhimurium (anti-O4) and anti-S. Enteritidis (anti-O9) IgM 
and IgG were measured at birth, 4 or 6 months, 9 months, and 
12  months. The dynamics of antibody titers for anti-O4 and 
anti-O9 IgM and IgG over the first 12 months of life were inves-
tigated using GAMM models (Figure  2). The GAMM-fitted 
anti-O4 and anti-O9 IgM trend lines originated below the limit 
of detection and steadily increased at a slowing rate over the 
12-month period (Figure 2A and C). Conversely, the anti-O4 
and anti-O9 IgG trend lines declined over several months 
and then sporadically increased, likely reflecting exposure to 
O4- and O9-positive organisms (Figure 2B and 2D) . The low-
est point of the GAMM-fitted IgG trend lines for anti-O4 and 
anti-O9 IgG was between 20 and 30 weeks of age.
Seroconversion was defined as a ≥2-fold increase in IgG titer 
against the respective O antigen. Over the follow-up period 
in our infant population, we observed 179 and 167 serocon-
versions to O4 and O9, respectively, with 120 infants serocon-
verting to both antigens, indicating some O antigen specificity 
(Supplementary Figure 3). Of the 503 enrolled infants, 359 were 
followed up for the 12-month period. We estimated the sero-
incidence of group B (most commonly S. Typhimurium) and 
group D (most commonly S. Enteritidis) Salmonella exposures 
100
1000
100 1000
Maternal α−S. Typhimurium IgG Titer (EU) Maternal α−S. Enteritidis IgG Titer (EU)
N
ew
bo
rn
 α
−S
. T
yp
hi
m
ur
iu
m
Ig
G
 T
ite
r 
(E
U
)
N
ew
bo
rn
 α
−S
. E
nt
er
iti
di
s
Ig
G
 T
ite
r 
(E
U
)
100
1000
100 1000
r = .85
Transfer ratio = 1.45
r = .87
Transfer ratio = 1.23
P < .0001 P < .0001
BA
Figure 1. High transplacental transfer of anti-Salmonella enterica serovar Typhimurium antibodies (ie, O4-specific immunoglobulin G [IgG]) and anti-S. enterica serovar 
Enteritidis antibodies (ie, O9-specific IgG) from mothers to newborns. Titers of anti-S. Typhimurium–specific IgG (A) and anti-S. Enteritidis–specific IgG (B) show statistically 
significant positive correlation between paired maternal blood and infant cord-blood samples, with a high transfer ratio (ie, maternal to infant IgG ratio). The correlation 
between log10-transformed newborn and maternal IgG titers was tested using the Pearson correlation test.
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during the first 12 months of infant life as 475 episodes/1000 
infant-years (95% CI, 410–547) and 448 episodes/1000 infant-
years (95% CI, 385–518), respectively (Table 4). We additionally 
observed that there were no O4 and O9 Salmonella seroconver-
sions from 0 to 4 months of age, while the rate of seroconver-
sion increased significantly between 5 and 9 months and again 
between 10 and 12 months (Table 4).
Infants Protected Against Seroconversion to O Antigen by Maternally 
Acquired IgG
A lack of seroconversion during 0–4 months of age (Figure 2B 
and D) combined with an increasing seroincidence rate with 
age (Table  4) implied increased susceptibility of infants to 
Salmonella infections as a consequence of the decay of pro-
tective maternal antibodies or, alternatively, an increase in 
the exposure to these organisms after weaning. Infants who 
seroconverted at 10–12 months of age and those who did not 
seroconvert during the first 12 months of life had significantly 
greater anti-S. Typhimurium (anti-O4) and anti-S. Enteritidis 
(anti-O9) IgG titers at birth than those who seroconverted at 
5–9 months of age (Figure 3A and B). Last, we measured the 
functional capacity of maternally acquired O4- and O9-specific 
antibodies to induce complement-mediated bacterial killing. In 
vitro serum bactericidal assays using a Vietnamese wild-type 
Table 2. Linear Risk Factor Models for the Log10-Transformed Anti-O4 Antigen–Specific Immunoglobulin G (IgG) Transfer Ratio as a Function of Several 
Maternal and Neonatal Covariates
Variable
Univariate Analysis Multivariate Analysis
β (95% CI) P Adjusted β (95% CI) Pa
Maternal age, y −0.001 (−.005–.002) .436 …
Maternal education level, higher secondary or above 0.01 (−.02–.04) .592 …
Maternal O4 antigen–specific IgG level, log10 transformed −0.09 (−.14 to −.04) .0003 −0.09 (−.14 to −.04) .0006
Preterm birth, gestation <37 wk −0.11 (−.20 to −.03) .009 −0.11 (−.19 to −.02) .012
Low birth weight, <2500 g −0.04 (−.12 to .04) .377 …
Female neonatal sex 0.04 (.003 to .07) .034 0.03 (−.004 to .06) .085
Smoking or passive smoking during pregnancy 0.02 (−.02 to .05) .295 …
Irregular vaginal bleeding −0.08 (−.16 to −.001) .049 −0.07 (−.15 to .003) .061
Diabetes 0.03 (−.05 to .12) .414 …
Intrauterine growth restriction −0.01 (−.11 to .010) .879 …
Maternal hypertension 0.07 (.001 to .13) .048 0.07 (.01 to .14) .027
Maternal anemia 0.01 (−.06 to .08) .789 …
Fever from infection during pregnancy 0.003 (−.076 to .081) .947 …
Abbreviation: CI, confidence interval.
aFor adjusted coefficients from the final multivariate risk factor model.
Table  3. Linear Risk Factor Models for Log10-Transformed Anti-O9 Antigen–Specific Immunoglobulin G (IgG) Transfer Ratio as a Function of Several 
Maternal and Neonatal Covariates
Variable
Univariate Analysis Multivariate Analysis
β (95% CI) P β (95% CI) Pa
Maternal age, y −0.001 (−.004–.002) .492 …
Maternal education level, higher secondary or above 0.01 (−.02–.05) .510 …
Maternal O9 antigen–specific IgG level, log10 transformed −0.001 (−.06 to .04) .703 …
Preterm birth, gestation <37 wk −0.08 (−.17 to .001) .056 −0.11 (−.19 to −.02) .063
Low birth weight, <2500 g −0.02 (−.10 to .06) .558 …
Female neonatal sex 0.04 (.005 to .07) .024 0.03 (−.002 to .07) .048
Smoking or passive smoking during pregnancy −0.003 (−.04 to .03) .874 …
Irregular vaginal bleeding −0.07 (−.15 to .01) .105 −0.07 (−.15 to .01) .086
Diabetes 0.04 (−.04 to .12) .335 …
Intrauterine growth restriction −0.01 (−.12 to .09) .785 …
Maternal hypertension 0.07 (.004 to .14) .037 0.08 (.01 to .14) .028
Maternal anemia 0.01 (−.06 to .08) .741 …
Fever from infection during pregnancy 0.05 (−.03 to .13) .230 …
Abbreviation: CI, confidence interval.
aFor adjusted coefficients from the final multivariate risk factor model.
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S. Typhimurium showed that paired maternal and infant cord 
plasma samples with high titers (>1000 EU) of anti-O4 IgG anti-
bodies induced significantly greater serum bactericidal activity 
than those with low (<50 EU) anti-O4 IgG titers (Figure 3C). 
This observation indicates a protective role of maternally 
acquired antibodies during the early months of infant life and 
indicates a correlation between antibody titer and the ability to 
induce complement-mediated killing.
DISCUSSION
We conducted a seroepidemiologic investigation of NTS-specific 
antibodies in a large number of mothers and their infants in the 
first year of life in urban Vietnam. Because mothers were recruited 
to the study prior to giving birth, we had the ability to collect data 
regarding complications during pregnancy and the mother’s con-
dition prior to delivery. Additionally, the 1-year follow-up period 
allowed us to measure the longevity of maternal antibodies and 
to accurately determine the seroincidence of NTS in infants in 
HCMC. Our study defines the role and dynamics of NTS-specific 
maternal antibodies and better estimates the true burden of NTS 
infections in infants residing in a setting of endemicity.
Our study observed higher antibody concentrations of both 
anti-O4– and anti-O9–s––– pecific IgG in newborns than 
mothers at delivery. Similar observations have been observed 
with antibodies specific to other pathogens, such as influ-
enza virus, measles virus, and Bordetella pertussis [14, 30, 31]. 
Because of the recent implementation of maternal vaccina-
tion to protect neonates from life-threatening infections, there 
has been considerable interest in factors affecting the transfer 
rates of antibodies to infants to optimize protection provided 
by prenatal vaccination [14, 32, 33]. Factors such as maternal 
antibody concentration [31, 34], IgG subtype [35, 36], antigen 
target [37], gestation age [35, 36] and pregnancy complications 
(such as hypertension) [38, 39] have been shown to affect trans-
fer rates of antibodies specific to other antigens, such as measles 
virus, LPS (from Klebsiella pneumoniae, Escherichia coli, and 
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Figure 2. Antibody dynamics of Salmonella enterica serovar Typhimurium–specific antibodies (ie, O4) and S. enterica serovar Enteritidis–specific antibodies (ie, O9) during 
the first 12 months of life in infants from Ho Chi Minh City, Vietnam. Plots show a generalized additive mixed-effect model–fitted population trend (solid black line) for anti-O4 
immunoglobulin M (IgM; A), anti-O4 immunoglobulin G (IgG; B), anti-O9 IgM (C), and anti-O9 IgG (D) from birth through 12 months of age. 95% confidence intervals are shown 
by the dashed black lines.
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Pseudomonas aeruginosa), tetanus toxoid, diphtheria toxoid, 
and pertussis antigens [26]. We identified maternal antibody 
levels and preterm birth to be negatively associated and mater-
nal hypertension to be positively associated with the transfer 
ratio of anti-O4– and anti-O9–specific IgG. Negative associa-
tions between maternal antibody levels and transfer ratios have 
been observed previously and occur because of the saturation 
of the transplacental IgG transporter (ie, the fetal Fcγ receptor) 
in environments with high maternal IgG titers [26]. Despite this 
negative association, fetuses will still benefit from prenatal vac-
cination because children born to mothers with high IgG titers 
will also have high IgG concentrations.
A larger cohort, in whom the present study was nested, esti-
mated the symptomatic diarrheal disease incidence in infants 
between 2009 and 2013 to be 89.4 cases/1000 infant-years, 
of which 18% (approximately 16.1 cases/1000 infant-years) 
involved stool specimens that were PCR positive for Salmonella 
[19, 21]. However, the true burdens of S. Typhimurium and 
S. Enteritidis infections (symptomatic and asymptomatic) in 
Vietnamese infants, as estimated here by the seroincidence, 
were significantly greater, at 475 cases/1000 Infant-years and 
448 cases/1000 infant-years, respectively. The high seroinci-
dences indicate that the underlying transmission dynamics of 
S. Typhimurium and S. Enteritidis infections in the Vietnamese 
infant population are far greater than estimated in prior studies 
[19, 21]. Therefore, public health control measures, potentially 
including vaccination and improved farm biosafety, are required 
to reduce transmission of S. Typhimurium and S. Enteritidis in 
this vulnerable age group [40, 41].
Our investigation also suggests that maternally acquired 
antibodies offer protection from NTS infections during the first 
months of infant life. Similar observations have been made in 
a Malawian pediatric cohort, which attributed limited invasive 
NTS disease during early infant life to transplacentally acquired 
antibodies [9, 18, 42]. Furthermore, our time-trend analysis 
showed that infants in urban Vietnam were most vulnerable 
to NTS infections (ie, the point of lowest immunity against 
S. Typhimurium and S. Enteritidis offered by maternally acquired 
antibodies) between 20 and 30 weeks of age. Estimation of the 
lowest passive immunity to S. Typhimurium and S. Enteritidis 
at the population level provides vital information for scheduling 
the delivery of future NTS vaccines, as has been the case with 
several successfully licensed infant vaccines [33, 43].
Although the majority of NTS disease cases occur during the 
first and second years of life [9], infants aged <1 year experience 
the greatest incidence of bacteremia-related deaths in Kenya and 
compose the age group that would benefit the most from NTS vac-
cination [44]. Therefore, current opinion is that vaccines against 
S. Typhimurium and S. Enteritidis should be given at 2–4 months 
of age [5]. However, polysaccharide vaccines in children aged 
<2 years elicit only weak antibody responses, and even conjuga-
ted polysaccharide vaccines induce poorer immune responses in 
neonates than in older children [45–47]. Maternal immunization 
during pregnancy is becoming an accepted strategy to protect 
infants from life-threatening infections such as tetanus, pertussis, 
and influenza [11, 48]. Taking into account observations from 
this study and existing evidence, we propose maternal immuniza-
tion during pregnancy as a sensible strategy to prevent NTS dis-
ease during infancy and to delay infant immunization until 9 or 
12 months of age, when it can be easily integrated with the existing 
Expanded Program on Immunization schedule.
Our study had several limitations. We were unable to esti-
mate cumulative seroincidences for S. Typhimurium and 
S. Enteritidis infections, since some participating infants were 
lost to follow-up and therefore not followed until 1 year of age. 
Furthermore, only a maximum of 4 longitudinal plasma sam-
ples were collected from participating infants over the span 
of 1  year; this sampling frequency may have induced inaccu-
racy in the time-trend models. Additionally, although other 
group B and D Salmonella organisms are less common than 
S. Typhimurium and S. Enteritidis in Vietnam [49], the cross-re-
activity from other Salmonella bacteria within the same group 
may introduce error.
NTS are associated with millions of infant cases of gastro-
enteritis and bacteremia globally, and mortality rates are likely 
to worsen as a consequence of antimicrobial resistance against 
key antimicrobials [50]. There are currently no human-approved 
NTS vaccines, although several are in the preclinical phase [5]. 
Our seroepidemiologic investigation defines the importance 
of maternally acquired antibodies for neonatal protection and 
suggests that the extent of NTS circulation and infant exposure 
in Vietnam is substantially larger than previously estimated 
[19]. Our study provides evidence of high NTS transmission in 
this setting and proposes maternal immunization as a potential 
control strategy against NTS disease in infants.
Table  4. Estimated Seroincidences of Salmonella Serogroup B and D 
Detection During the First Year of Life Among Infants in Ho Chi Minh City
Salmonella  
Serogroup
Seroincidence,  
Cases/1000 Infant-Years, 
Mean (95% CI) P
Group B
 First year of life 475 (410–547)
Age, mo
  0–4 0 (0–29)
  5–9 536 (418–677) <.00001a
  10–12 654 (487–860) .276b
Group D
 First year of life 448 (385–518)
 Age, mo
  0–4 0 (0–29)
  5–9 474 (364–608) <.00001a
  10–12 847 (655–1077) .0009b
Abbreviation: CI, confidence interval.
aBy the Wald test, comparing incidence rates between ages 0–4 months and 5–9 months.
bBy the Wald test, comparing incidence rates between ages 5–9 months and 10–12 months.
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Figure 3. Protective role of maternally acquired nontyphoidal Salmonella (NTS)–specific immunoglobulin G (IgG) antibodies in infants. Seroconversion in younger age 
groups was associated with significantly lower Salmonella enterica serovar Typhimurium–specific IgG (ie, O4; A) and S. enterica serovar Enteritidis–specific IgG (ie, O9; B) 
titers at birth. *P > .01 but ≤ .05, **P ≥ .001 but ≤ .01, and ***P < .001, by the Mann-Whitney U test. C, Maternal plasma specimens with either high (ie, >1000 EU; n = 11) or 
low (ie, <50 EU; n = 9) anti-S. Typhimurium IgG binding titers (along with the paired cord plasma specimens) were tested for serum bactericidal assay (SBA) activity against a 
clinical isolate of S. Typhimurium. *P > .01 but ≤ .05, **P ≥ .001 but ≤ .01, and ***P < .001, by the paired Wilcoxon test, for comparison of SBA titers between paired maternal 
and cord plasma specimens, and by the Mann-Whitney U test, for comparison of SBA titers across high and low anti-S. Typhimurium IgG binding antibody titer groups. The red 
dashed lines at the top and bottom mark the maximum and minimum plasma dilutions, respectively, used in the assay. The numbers of maternal-infant pairs with high-binding 
and low-binding titers used in the assay were 11 and 9, respectively.
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